CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
Placebo +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02693782
NCT02693782N/ACompleted

Effect of Wheat Bran Extract Containing Arabinoxylan Oligosaccharides, on the Gut Microbiota Composition and Well-being in Healthy Aging Subjects PhD Project: New Targeted Prebiotic Approaches for Maintaining Human Health

University of Aberdeen·interventional·Posted Feb 29, 2016·Updated May 2, 2017

In Brief

A clinical study evaluating Placebo and Fibre supplement for Hypercholesterolemia and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This is a placebo controlled, cross-over, randomized, double blinded study. The intervention food products will be taken as diet prebiotic supplements: 1. Wheat Bran Extract rich in arabinoxylan oligosaccharides : 15g/d (up to 10 g total additional dietary fibre per day). 2. Placebo product maltodextrin:equal amounts of a digestible carbohydrate. Primary endpoints are faecal microbiota analysis and faecal metabolite analysis (particularly, short chain fatty acid). Secondary endpoint is serum cholesterol, glucose, HDL and bowel function, gastrointestinal tolerance, quality of life and food frequency (by the use of questionnaires).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
CollaboratorsCargill

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 29, 2016
Enrollment StartJun 1, 2015
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.3 years ago

Interventions

Placebodietary

15 g/day maltodextrin in 3 portions of 5 g.

Fibre supplementdietary

15 g/day Wheat Bran Extract in 3 portions of 5 g.